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Previous results demonstrated that 10Hz electroacupuncture (EA) of Anmian acupoints in rats during the dark period enhances
slow wave sleep (SWS), which involves the induction of cholinergic activity in the caudal nucleus tractus solitarius (NTS) and
subsequent activation of opioidergic neurons and μ-receptors. Studies have shown that diﬀerent kinds of endogenous opiate
peptides and receptors may mediate the consequences of EA with diﬀerent frequencies. Herein, we further elucidated that high-
frequency (100Hz)-EA of Anmian enhanced SWS during the dark period but exhibited no direct eﬀect on rapid eye movement
(REM) sleep. High-frequency EA-induced SWS enhancement was dose-dependently blocked by microinjection of naloxone or
κ-receptor antagonist (nor-binaltorphimine) into the caudal NTS, but was aﬀected neither by μ- (naloxonazine) nor δ-receptor
antagonists (natatrindole), suggesting the role of NTS κ-receptors in the high-frequency EA-induced SWS enhancement. Current
and previous results depict the opioid mechanisms of EA-induced sleep.
1.Introduction
Neuropeptides, along with neurotransmitters, mediate vari-
ous underlying mechanisms of neural functions and behav-
iors(e.g.,opioidpeptidesinpaincontrol[1],corticotrophin-
releasing hormone (CRH) in stress-related behavior and
sleep-wake regulation [2], hypocretin in feeding behavior
and in the maintenance of vigilance states [3], etc.). Discov-
ery of endogenous opioid peptides, including β-endorphin,
dynorphin, enkephalin, and endomorphin, in the central
nervous system (CNS) reveals the mysterious actions of
acupuncture, especially in its analgesic eﬀect. It had ﬁrst
been demonstrated that the acupuncture-induced analgesic
eﬀect could be blocked by a broad-spectrum opioid receptor
antagonist naloxone in both humans and mice [4, 5],
implicating the role of endogenous opioid peptides. Cheng
and Pomeranz had revealed that relatively low doses of
naloxone only block the analgesic eﬀect induced by low
frequency (4Hz) of electroacupuncture (EA) stimulation,
butnottheconsequenceinducedbyhighfrequency(200Hz)
of EA [6], suggesting that the low frequency, rather than the
high frequency, of EA increases the release of endogenous
opioids. Nevertheless, Han and his colleagues have further
shown that the increase of endogenous opioids mediates2 Evidence-Based Complementary and Alternative Medicine
the analgesic eﬀects induced by both the low-frequency
and high-frequency EA stimuli by employing distinct opioid
receptor subtype-speciﬁc antagonists [7, 8]. While μ-a n d
δ-opioid receptors in the spinal cord are dominant in
the low-frequency EA-induced analgesia, κ-opioid receptors
contribute to the high-frequency EA eﬀects [7, 8]. Radioim-
munoassay of spinal perfusates from rats receiving various
frequencies of EA stimulations further indicates that 2Hz
EA enhances enkephalin (a mixed μ-a n dδ-opioid receptor
agonist) immunoreactivity (IR), but not the dynorphin (κ-
opioid receptor agonist) IR. In contrast, 100Hz EA increases
dynorphin IR rather than enkephalin IR [9].
Our previous results have shown that 10Hz EA at
Anmian (EX17) acupoints increases slow wave sleep (SWS)
in rats, which involves the induction of cholinergic activity
in the caudal nucleus tractus solitaries (NTS) [10, 11].
The NTS is located in the dorsomedial medulla oblongata.
Ascending projections from the NTS are traced through
the lateral and dorsal tegmentum and periventricular gray
up to the rostral pons and midbrain and terminate in
the parabrachial nucleus, which in turn projects to the
thalamus, hypothalamus, preoptic area, bed nucleus of the
stria terminalis, amygdala, and the frontal cortex, regions
commonly belonging to the visceral-limbic forebrain [12,
13]. From these anatomical data, it does not appear that the
predominant eﬀect of the NTS is via the reticular-activating
system but instead is via limbic forebrain structures, which
are implicated in the sleep regulation. Furthermore, the low-
frequency electrical stimulation of the medullary reticular
formation, particularly the dorsal reticular formation and
the caudal NTS, produces cortical synchronization indicative
of SWS in an awake animal [14]. Conversely, lesions of
the dorsal reticular formation and of the NTS produced
desynchronization of the EEG in a sleeping animal [15].
These results all suggest that the existence of neurons
in the NTS is involved in generating sleep. Furthermore,
microinjection of morphine into the NTS provokes an
enhancement of SWS and this eﬀect is blocked by naloxone
[16], suggesting the somnogenic eﬀect of opioidergic system
in the NTS. The involvement of opioidergic system in
EA’s therapeutic indications other than the analgesia (e.g.,
insomnia) has been less discussed in literature. Our previous
studyhasrevealedthat10Hz(lowfrequency)EAstimulation
of Anmian acupoints increases the concentrations of β-
endorphin in the brainstem, which consequently enhances
SWS through activation of the μ-opioid receptors, rather
than the δ-a n dκ-opioid receptors, in the caudal NTS [11].
However, it has never been determined whether diﬀerent
frequencies of EA stimulations at Anmian acupoints activate
distinct opioid receptors in the NTS. This current study
was designed to clarify what type(s) of opioid receptor is
(are) involved in high-frequency (100Hz) EA-induced sleep
alterations.
2.MaterialsandMethods
2.1. Pharmacological Agents. Stock solutions of a broad spec-
trum opioid antagonist (naloxone hydrochloride (Tocris,
Bristol, UK)), a μ-receptor antagonist (naloxonazine dihy-
drochloride (Tocris)), a δ-receptor antagonist (naltrindole
hydrochloride (Tocris)), and a κ-receptor antagonist (nor-
binaltorphimine dihydrochloride (Tocris)) were dissolved in
pyrogen-free saline (PFS). The stock solutions were stored at
4◦C until use. Our previous results and others have indicated
that the appropriate microinjection dosage for naloxonazine,
naltrindole, and nor-binaltorphimine to selectively block μ-
, δ-, and κ-opioid receptors, without interaction with other
opioid receptor subtypes, is within 20μg[ 11, 17, 18]. In
current study, naloxone, naloxonazine, naltrindole, and nor-
binaltorphimine were microinjected at three diﬀerent doses,
0.1, 1.0, and 10μg/μL. The total volume used for each
microinjection was 1μL.
2.2.Animals. MaleSprague-Dawleyrats(250–300g;Nation-
alLaboratoryAnimalBreedingandResearchCenter,Taiwan)
were used in this study. Rats were anesthetized by intraperi-
toneal injection with ketamine/xylazine (87/13mg/kg) and
were given an analgesic (1mg/rat morphine) and an antibi-
otic (5000IU/rat penicillin G benzathine) to reduce pain and
avoid infection. Rats were surgically implanted with three
electroencephalogram (EEG) screw electrodes as previously
described [19] and a microinjection guide cannulae directed
into the caudal NTS (AP, -13.30mm from bregma; ML,
1.2mm; DV, 8.2mm relative to bregma). The coordinates
were adopted from the Paxinos and Watson rat atlas [20].
Two unilateral screw EEG electrodes were placed over the
right hemisphere of the frontal and parietal cortices, and
a third EEG electrode was placed over the cerebellum and
served to ground the animal to reduce signal artifacts.
Insulated leads from EEG electrodes were routed to a Teﬂon
pedestal (Plastics One, Roanoke, VA, USA). The Teﬂon
pedestal was then cemented to the skull with dental acrylic
(Tempron, GC Co., Tokyo, Japan). The incision was treated
topically with polysporin (polymixin B sulfate-bacitracin
zinc), and the animals were allowed to recover for seven days
prior to the initiation of experiments. The rats were housed
separately in individual recording cages in the isolated room,
in which the temperature was maintained at 23 ± 1◦Ca n d
the light:dark rhythm was controlled in a 12:12h cycle
(40 Watt × 4 tubes illumination). Food (5001 rodent diet,
LabDiet) and water were available ad libitum.A l lp r o c e d u r e s
performed in this study were approved by the National
Taiwan University Animal Care and Use Committee.
2.3. Experimental Protocol. On the 2nd postsurgical day, the
rats were connected to the recording apparatus (see below)
via a ﬂexible tether. As such, the rats were allowed relatively
unrestrictedmovementwithintheirowncages.Threegroups
of rats were used in the study as follows: group 1 (n = 8) was
used to determine the eﬀects of opioid receptor antagonist
(naloxone) on 100Hz EA-induced alterations in sleep; group
2 (n = 8) was used to depict the eﬀects of μ-receptor antago-
nist (naloxonazine) on 100Hz EA-induced sleep alterations;
group 3 (n = 8) was used to elucidate the eﬀects of δ-
receptor antagonist (naltrindole) and κ-receptor antagonist
(nor-binaltorphimine) on 100Hz EA-induced alterations inEvidence-Based Complementary and Alternative Medicine 3
sleep. One week after rats had adapted to the 12:12-hour
light:dark cycle after surgery, 24-hour undisturbed baseline
recordings were obtained beginning at dark onset on the
1st recording day in rats from all groups. When 100Hz
EA was given (see later), all rats were lightly anesthetized
with one-third of the dose of ketamine/xylazine used in the
s u r g e r y ,a f t e rw h i c hr a tw o k eu pi n2 0t o2 5m i n u t e s .A
twenty-minute period of EA stimulation was administered
before the onset of the dark period. The anesthetization
was given 25 minutes prior to the dark period onset and
lasted for 20 minutes. The rationale for carrying out the
experimentinthedarknessisthatratsareactivewithalowest
level of sleep during the dark period, and a manipulation,
if it possesses ability to increase sleep, would signiﬁcantly
augment sleep during the dark period. In contrast, it may
not be easy to enhance sleep during the light period when
sleep activity is at its highest circadian level. Since we
expected to ﬁnd a sleep enhancement after the 100Hz EA
stimuli at the Anmian (EX17), we therefore manipulated
the EA stimulation before the onset of the dark period
and analyzed the sleep alteration during the subsequent
dark period. The rats in group 1 were intraperitoneally (IP)
administeredPFSandmicroinjectedwithPFSintothecaudal
NTS ( ipPFS+ PFS) at 25 minutes prior to the dark onset on
two consecutive days, and recordings were obtained for 24h
beginningafterthesecondinjection.Theeﬀectsofanesthesia
with the NTS microinjection of PFS ( ipketamine +PFS) on
sleepweredeterminedafterIPinjectionofketamine/xylazine
and the NTS PFS microinjection on two consecutive days. A
100Hz sham EA ( ipketamine +PFS+sham EA) was deliv-
ered to control for the nonspeciﬁc eﬀect of the electrical
stimulation, although our previous study had conﬁrmed
that no nonspeciﬁc eﬀect was observed after the sham
EA [10, 11]. The 100Hz EA stimuli under anesthesia
( ipketamine + PFS+ EA) were also performed before the
dark onset on two consecutive days, and sleep-wake behavior
afterthesecond100HzEAstimulationwasthendetermined.
Subsequently, three diﬀerent doses (0.1, 1.0, and 10μg) of
naloxone ( ipketamine +naloxone+EA) were administered
25 minutes prior to the dark onset on the second day of
100Hz EA stimulation, and the 24h sleep pattern was deter-
mined. At least one day without injections was scheduled
between each manipulation. The 100Hz EA stimulus was
delivered via the bilateral insertion of stainless needles (32
gauge × 1  , Shanghai Yanglong Medical Articles Co.) on
Anmian (EX17) points in the depth of 2mm. The stimulus
consisted of a train of biphasic pulses (150μsd u r a t i o ne a c h )
of 100Hz with intensity of 3mA and was delivered by
Functions Electrical Stimulator (Trio 300, I.T.O., Japan). The
acupoint “Anmian (EX17)” is located at midpoint between
Yifeng (TH 17) and Fengchi (GB 20); Yifeng (TH 17) locates
posterior to the lobule of the ear in the depression between
the mandible and mastoid process; Fengchi (GB 20) locates
inthedepressionbetweentheupperportionofm.sternoclei-
domastoideus and m. trapezius in human. The location of
Anmian (EX17) in rats is at the relative anatomical location
between the sternocleidomastoideus muscle and the splenius
capitis muscle, as in the human acupoint map. Sham EA was
performed by stimulation of a nonacupoint located at the
ventral conjunction between the forelimb and the trunk as
previous described [10]. Rats in group 2 received a similar
protocolasthoseingroup1,exceptthatthesubstanceadmin-
istered was naloxonazine ( ipketamine + naloxonazine + EA).
T h o s er a t si ngroup 3 underwent a similar protocol as those
in groups 1 and 2, except that the substances administered
were naltrindole ( ipketamine +naltrindole +EA) and nor-
binaltorphimine ( ipketamine + nor-binaltorphimine + EA).
There was a week interval between the administrations of
three doses of naltrindole and those of three doses of nor-
binaltorphimine.
2.4. Apparatus and Recording. Signals from the EEG elec-
trodes were fed into an ampliﬁer (Colbourn Instruments,
Lehigh Valley, PA; model V75-01). The EEG was ampliﬁed
(factor of 5,000) and analog bandpass ﬁltered between 0.1
and 40Hz (frequency response: ±3dB;ﬁlterfrequencyroll
oﬀ: 12dB/octave). Gross body movements were detected by
custom-made infrared-based motion detectors (Biobserve
GmbH,Germany),andthemovementactivitywasconverted
to a voltage output which was digitized and integrated into
1-s bins. These conditioned signals (EEGs and gross body
movements) were subjected to analog-to-digital conversion
with 16-bit precision at a sampling rate of 128Hz (NI PCI-
6033E; National Instruments, Austin, TX). The digitized
EEG waveform and integrated values for body movement
were stored as binary computer ﬁles pending subsequent
analyses.
Postacquisition determination of the vigilance state was
done by visual scoring of 12-s epochs using custom software
(ICELUS, Mark R. Opp) written in LabView for Windows
(National Instruments). The animal’s behavior was classiﬁed
as either SWS, REM sleep, or waking based on previously
deﬁned criteria [21]. Brieﬂy, SWS is characterized by large-
amplitude EEG slow waves, high power density values in the
delta frequency band (0.5–4.0Hz), and lack of gross body
movements. During REM sleep, the amplitude of the EEG is
reduced, the predominant EEG power density occurs within
the theta frequency (6.0–9.0Hz), and there are phasic body
twitches. During waking, the rats are generally active. There
areprotractedbodymovements.TheamplitudeoftheEEGis
similartothatobservedduringREMsleep,butpowerdensity
values in the delta frequency band are generally greater than
those in theta frequency band.
2.5. Statistical Analyses for Experiment Protocol. All values
acquired from sleep-wake recording were presented as the
mean ± SEM for the indicated sample sizes. One-way
analyses of variance (ANOVA) for the duration of each
vigilance state (SWS, REM sleep, WAKE) and for sleep
architecture parameters were performed, comparing before
and after manipulation within subjects, across a certain of
time block. An α level of P ≤ 0.05 was taken as indicating
a statistically signiﬁcant diﬀerence. If statistically signiﬁcant
diﬀerences were detected, a Scheﬀe post hoc comparison
was made to determine which hourly intervals during
experimental conditions deviated from values obtained from
the same animals during control conditions.4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: The eﬀects of high-frequency (100Hz) stimulation by EA at Anmian (EX17) acupoints on vigilance states and the
eﬀect of naloxone. Shade area: ipPFS+PFS, open circles: ipketamine +PFS, closed circles: ipketamine + PFS+EA, open triangles:
ipketamine + naloxone (10 μg) +EA. ∗represents a statistically signiﬁcant diﬀerence between the values obtained from ipketamine +PFS
and ipPFS+ PFS. §depicts a statistically signiﬁcant diﬀerence between the values obtained from ipketamine +PFS+ EA and
ipketamine + PFS. #demonstrates a statistically signiﬁcant diﬀerence between the values obtained from ipketamine + PFS+EA and
ipketamine + naloxone + EA. The black horizontal bar on the x-axis represents the dark period of the 12:12h light:dark cycle. REM refers
to rapid eye movement; SWS slow wave sleep.
3. Results
3.1. The Eﬀect of Naloxone on the 100Hz EA-Induced Alter-
ations in Sleep. Anesthetization of rats for 25 minutes with
ketamine/xylazine prior to the dark period suppressed both
SWS and REM sleep during the ﬁrst few hours of the dark
period, which is consistent with our previous ﬁndings, and
the possible mechanisms were discussed later [10, 11]. The
percentage of time spent in SWS during the ﬁrst 2h period
after ipketamine +PFS was decreased from 22.4 ±3.8%
acquired after ipPFS+PFS t o 5 .2 ± 1.4% (P<0.05;
Figure 1(a)); however, no signiﬁcant alteration was detected
when SWS during the 12h of the dark period was analyzed
in group 1 (F = 1.269, nonsigniﬁcance (n.s.); Figure 1(b)).
REM sleep was signiﬁcantly suppressed from 5.5 ± 0.6%
obtained after ipPFS+PFS to 3.3 ± 0.6% acquired after
ipketamine +PFS during the 12h of the dark period (F =
18.823, P<0.01; Figure 1(d)), especially during the ﬁrst
3h after the administrations (Figure 1(c)). Application of
100Hz sham EA did not alter any aspect of sleep parametersEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: The eﬀects of naloxonazine on 100Hz EA-induced alterations in sleep. Shade area: ipPFS + PFS, open circles: ipketamine +PFS,
closed circles: ipketamine +PFS+ EA, open triangles: ipketamine + naloxonazine (10μg)+EA. ∗represents a statistically signiﬁcant
diﬀerence between the values obtained from ipketamine + PFS and ipPFS+PFS. §depicts a statistically signiﬁcant diﬀerence between the
values obtained from ipketamine + PFS+EA and ipketamine + PFS.
(data not shown), which is similar to our previous observa-
tion [10, 11]. Twenty minutes of 100Hz EA stimuli delivered
before the dark period on two consecutive days signiﬁcantly
augmented SWS during the postmanipulation hours 5–8
and hour 11 (Figure 1(a)). Analysis of 12 h dark period
revealed that SWS was enhanced from 14.8 ± 1.6% after
ipketamine +PFSto21.2±1.6%after ipk etami n e+PFS+EA
(F = 9.392, P<0.05; Figure 1(b)). The percentage
of time spent in SWS during hours 5–8 increased from
17.5 ± 2.1% obtained after ipketamine +PFS to 29.3 ±
2.6% after ipketamine +PFS+EA (P<0.05; Figure 1(a)).
The percentage of SWS during the 11h was also enhanced
from 28.0 ± 7.3% to 36.9 ± 4.2% (P<0.05; Figure 1(b)).
However, REM sleep was not signiﬁcantly altered by 100Hz
EA (Figures 1(c) and 1(d)).
Administration of three diﬀerent doses (0.1, 1.0, and
10.0μg) of naloxone, a broad spectrum opioid antagonist,
into the caudal NTS dose-dependently blocked 100Hz EA-
induced increases of SWS, especially during postmanipula-
tion hours 5–8 (Figures 1(a) and 1(b)). Across the entire
12 h dark period recording, SWS was suppressed from
21.2 ± 1.6% after ipketamine +PFS+EA to 16.7 ± 2.1%
after ipketamine + naloxone (10.0μg)+EA (F = 18.457,
P<0.05; Figures 2(a) and 2(b)), while no signiﬁcant6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: The eﬀects of naltrindole on 100Hz EA-induced alterations in sleep. Shade area: ipPFS + PFS, open circles: ipketamine +PFS,
closed circles: ipketamine + PFS+EA, open triangles: ipketamine +naltrindole (10 μg) +EA. ∗represents a statistically signiﬁcant diﬀerence
between the values obtained from ipketamine +PFS and ipPFS+ PFS. §depicts a statistically signiﬁcant diﬀerence between the values
obtained from ipketamine + PFS+EA and ipketamine + PFS.
alteration was detected in REM sleep after administration of
nalaxone into the caudal NTS.
3.2. The Eﬀect of Naloxonazine on the 100Hz EA-induced
Alterations in Sleep. In group 2, the eﬀects of ketamine
(suppression of SWS and REM sleep during the ﬁrst few
hours after administrations) and the enhancement of SWS
during hours 5–8 after receiving 100Hz EA stimuli were
reproduced as those discovered in group 1 (Figures 2(a)
and 2(c)). Administration of μ-opioid receptor antagonist,
naloxonazine, into the caudal NTS exhibited no signiﬁcant
eﬀect on the 100Hz EA-induced SWS enhancement (Figures
2(a)and2(b)).NaloxonazinealsohadnoeﬀectonREMsleep
(Figures 2(c) and 2(d)).
3.3. The Eﬀect of Naltrindole on the 100Hz EA-Induced
Alterations in Sleep. In group 3, the eﬀects of ketamine
(suppression of SWS and REM sleep during the ﬁrst few
hours after administrations) and the enhancement of SWS
during hours 5–8 and hours 11–12 after receiving 100Hz EA
stimuliwerealsoreproducedasthosefoundingroups1and2
(Figures 3(a) and 3(c)).Evidence-Based Complementary and Alternative Medicine 7
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Figure 4: The eﬀects of nor-binaltorphimine on 100Hz EA-induced alterations in sleep. Shade area: ipPFS +PFS, open circles:
ipketamine +PFS, closed circles: ipketamine +PFS+ EA, open triangles: ipketamine +nor-binaltorphimine (10 μg) +EA. ∗represents a
statistically signiﬁcant diﬀerence between the values obtained from ipketamine +PFS and ipPFS+PFS. §depicts a statistically signiﬁcant
diﬀerencebetweenthevaluesobtainedfrom ipketamine +PFS+ EAand ipketamine +PFS. #demonstratesastatisticallysigniﬁcantdiﬀerence
between the values obtained from ipketamine + PFS+EA and ipketamine +nor-binaltorphimine+ EA.
Administration of δ-opioid receptor antagonist, nal-
trindole, into the caudal NTS exhibited no signiﬁcant eﬀect
on the 100Hz EA-induced SWS enhancement (Figures 3(a)
and 3(b)). Naltrindole had no further eﬀect on REM sleep
(Figures 3(c) and 3(d)).
3.4. The Eﬀect of Nor-Binaltorphimine on the 100Hz EA-
Induced Alterations in Sleep. In group 3, our results indicate
that the enhancement of SWS during hours 5–8 and
hours 11-12 induced by 100Hz EA stimuli was dose-
dependently blocked by the κ-opioid receptor antagonist,
nor-binaltorphimine. The percentage of time spent in SWS
acrosstheentire12hdarkperiodwassuppressedfrom25.6±
2.6% obtained after ipketamine +PFS+EA to 21.1 ± 2.6%
(F = 3.574, n.s.), 19.3 ± 2.4% (F = 9.784, P<0.05),
and 19.0 ± 2.4% (F = 9.897, P<0.05; Figures 4(a) and
4(b)) after administrations of 0.1, 1.0, and 10μgo fnor-
binaltorphimine, respectively.8 Evidence-Based Complementary and Alternative Medicine
The eﬀect of nor-binaltorphimine on blocking the
100Hz EA-induced SWS enhancement dominantly occurred
during hours 4–7 and hours 11-12 (Figure 4(a)). Nor-
binaltorphimine exhibited no eﬀect on REM sleep (Figures
4(c) and 4(d)).
4. Discussion
Acupunctureandelectroacupuncture(EA)havebeenrecom-
mended as an alternative medicine for several therapeutic
indications by the World Health Organization (WHO),
such as alleviation of pain, reduction of inﬂammation, and
management of insomnia. The theory underlying EA is still
controversial, although the action of EA has been widely
discussed in literature. The discovery of endogenous opioid
peptides, including enkephalin, β-endorphin, dynorphin,
and endomorphin, since 1970s enhances the investigation of
underlying mechanisms of EA, especially in the EA-induced
analgesia. Three main receptor subtypes of the opioid
receptors, including the μ-, δ-, and κ-opioid receptors, in the
spinal cord have been indicated involve in the mechanisms
of EA-induced analgesia. Endomorphin and dynorphin are,
respectively, considered as the relatively pure μ-a n dκ-
opioid receptor agonists [22, 23], while enkephalin and β-
endorphin are mixed μ-a n dδ-opioid receptor agonists
(review [1, 24]). Han and his colleagues have revealed
that low-frequency (2Hz) EA increases met-enkephalin, but
not dynorphin, in the spinal cord; while high-frequency
(100HZ) EA increases the release of dynorphin rather
than that of met-enkephalin [9]. The stimulation of EA
betweenlowandhighfrequencies(e.g.,15Hz)activatesboth
enkephalins and dynorphins [9]. They further demonstrated
that the analgesic eﬀect induced by low-frequency EA
stimulation is mediated by μ- and/or δ-opioid receptors; in
contrast, high-frequency EA-induced analgesia is mediated
by κ-opioid receptors [7, 8]. These observations suggest that
diﬀerent endogenous opioid peptides would be released and
act on distinct opioid receptors in the spinal cord under
diﬀerent stimulating conditions of EA. However, the involve-
ment of opioid receptors in sleep alteration under diﬀerent
stimulating conditions of EA remains undetermined.
We previously demonstrated that 10Hz EA stimuli of
Anmian(EX17)acupointsinanesthetizedratsfor20minutes
prior to the beginning of the dark period of the light:dark
cycle in two consecutive days enhance SWS during the
subsequent dark period [10, 11]. Our results also implicated
that 10Hz EA-induced SWS enhancement may be mediated,
in part, by vagal cholinergic aﬀerents to the caudal NTS
[10, 11]. There are two anatomically distinct β-endorphin
pathways in the brain; the major pathway originates in the
arcuate nucleus, and the minor one is in the area of the
NTS of the caudal medulla [25]. Furthermore, dynorphin is
also expressed in neurons of the brainstem NTS [26]. The
anatomical distributions of opioid receptors and peptides in
the CNS have been well described by Mansour et al. [27].
The neurons containing proopiomelanocortin (POMC),
proenkephalin, and prodynorphin are abundant in the NTS
[27]. The μ-a n dκ-opioid receptors are localized in the
caudal NTS with a highly density; however, little or no δ-
opioid receptor can be observed in the brainstem, including
the NTS [27]. Our previous results have depicted that the
SWS enhancement after 10Hz EA of Anmian acupoints is
mediated by increasing the concentrations of β-endorphin
and activation of the μ-opioid receptors in the NTS [11].
Herein, we tried to further elucidate whether high-frequency
(100Hz) EA stimulation of Anmian acupoints also elicits
similar eﬀect of sleep enhancement and whether the sleep
alterations under diﬀerent EA stimulation conditions are
mediated by distinct opioid receptors. Our current results
demonstrated that 100Hz (high-frequency) EA stimuli of
Anmian(EX17)acupointsinanesthetizedratsfor20minutes
in two consecutive days enhanced SWS, but not REM
sleep, during the subsequent dark (active) period. The
enhancement of SWS after 100Hz EA is similar to that after
10Hz EA stimulation [11], indicating both low-frequency
(10Hz) and high-frequency (100Hz) EA stimuli possess
ability to alter SWS in the same direction. Application of
naloxone, a broad spectrum of opioid receptor antagonist,
was used to determine the involvement of NTS opioidergic
receptors in the 100Hz EA-induced increase of SWS. We
found that administration of naloxone directly into the
caudal NTS dose-dependently blocked 100Hz EA-induced
SWS enhancement during the dark period, implicating the
involvement of endogenous opiates in the caudal NTS. A
potential role for three major opioid receptors, μ-, δ-, and
κ-receptors, was then determined by application of speciﬁc
receptor antagonists. Our results demonstrated that nor-
binaltorphimine, a κ-opioid receptor antagonist, exhibited
a similar dose-dependent eﬀect on blocking 100Hz EA-
induced SWS enhancement as that of naloxone; whereas
naloxonazine (a μ-opioid receptor antagonist) and nal-
trindole(aδ-opioidreceptorantagonist)hadnoeﬀect.These
observations combined with our previous results—μ-opioid
receptors mediate 10Hz EA-induced SWS enhancement
[11]—suggest that distinct opioid receptors in the NTS
involve diﬀerent stimulation frequencies of EA-induced SWS
enhancement,whichissimilartotheunderlyingmechanisms
of EA-induced analgesia in the spinal cord as reported
by Han and his colleagues [1, 7]. Strategy by employing
pharmacological blockade to elucidate the involvement of
particular opioid receptors in 100Hz EA-induced sleep
alteration is appropriate. However, it would be of interest to
mimic the EA-induced sleep alteration by microinjection of
κ-receptor agonist, for example, dynorphin, into the NTS in
future.
In order to perform the 100Hz EA stimulation easily,
rats were lightly anesthetized. We found that both SWS
and REM sleep during the ﬁrst few hours of the dark
period were decreased after rats recovered from the ketamine
anesthetic. The decreases in SWS and REM sleep were
also observed in our previous study [10, 11]. Ketamine, a
cyclohexanone derivative, is used clinically as a dissociative
anesthetic agent both in humans and animals. Ketamine is
a noncompetitive N-methyl-D-aspartate (NMDA) receptor
antagonist that blocks cation channels [28]. It has been
demonstrated that administration of ketamine or MK-801,
another NMDA receptor antagonist, at subanesthetic dosesEvidence-Based Complementary and Alternative Medicine 9
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Figure 5: A hypothetical model by which diﬀerent frequencies of
EA Anmian (EX17) alter SWS through diﬀerent opioid receptors in
the caudal NTS. β-EN: β-endorphin; DYN: dynorphin.
produces a robust, dose-dependent increase in the intensity
of δ-power of the NREM sleep [29, 30]. Furthermore, the
eﬀect of MK-801 by increasing the metabolic rate in the
hippocampus and other limbic structures stimulates physi-
ological sleep that is similar to the sleep that follows sleep
deprivation, indicating the need of homeostatic recovery
[31]. Therefore, the suppression of NREM and REM sleep
after recovery from the ketamine anesthetization during the
beginning of the dark period may be due to a homeostatic
compensation to the previous anesthetic state. However, this
explanation needs to be further investigated.
5. Conclusion
In summary, our current results demonstrated that 100Hz
EA stimuli of Anmian (EX17) acupoints enhance SWS
and this enhancement is blocked by naloxone and nor-
binaltorphimine, implicating the mediation of κ-opioid
receptors. Compared to our previous observation of involve-
ment of μ-opioid receptors in 10Hz EA-induced SWS
enhancement, we concluded that μ-opioid receptors in
the caudal NTS mediate the low-frequency (10Hz) EA-
induced SWS alteration, while κ-opioid receptors mediate
thehigh-frequency(100Hz)EA-inducedSWSenhancement.
Adiagramelucidatingonehypotheticalmechanismbywhich
diﬀerent frequencies of EA at Anmian (EX17) alters sleep is
depicted in Figure 5.
Disclosure
This is not an industry-supported study. Authors have
indicated no ﬁnancial conﬂicts of interest.
Authors’ Contribution
C.-H. Cheng and P.-L. Yi contributed equally to this work
and should be considered coﬁrst authors.
Acknowledgments
This work was supported by National Science Council Grant
NSC95-2320-B-002-098-MY2. The authors thank Mr. Yi-
Fong Tsai’s technical assistance in this project.
References
[1] J.-S. Han, “Acupuncture and endorphins,” Neuroscience Let-
ters, vol. 361, no. 1–3, pp. 258–261, 2004.
[2] F.-C. Chang and M. R. Opp, “Corticotropin-releasing hor-
mone (CRH) as a regulator of waking,” Neuroscience &
Biobehavioral Reviews, vol. 25, no. 5, pp. 445–453, 2001.
[3] N. Tsujino and T. Sakurai, “Orexin/hypocretin: a neuropep-
tide at the interface of sleep, energy homeostasis, and reward
system,” Pharmacological Reviews, vol. 61, no. 2, pp. 162–176,
2009.
[4] D.J.Mayer,D.D.Price,andA.Raﬁi,“Antagonismofacupunc-
ture analgesia in man by the narcotic antagonist naloxone,”
Brain Research, vol. 121, no. 2, pp. 368–372, 1977.
[5] B. Pomeranz and D. Chiu, “Naloxone blocks acupuncture
analgesia and causes hyperalgesia: endorphin is implicated,”
Life Science, vol. 19, no. 11, pp. 1757–1762, 1976.
[6] R. Cheng and B. Pomeranz, “Electroacupuncture analgesia
could be mediated by at least two pain-relieving mechanisms;
endorphin and non-endorphin systems,” Life Sciences, vol. 25,
no. 23, pp. 1957–1962, 1979.
[7] J.-S. Han, X.-Z. Ding, and S.-G. Fan, “The frequency as the
cardinal determinant for electroacupuncture analgesia to be
reversed by opioid antagonists,” Acta Physiologica Sinica, vol.
38, no. 5, pp. 475–482, 1986.
[8] X. H. Chen and J.-S. Han, “Analgesia induced by elec-
troacupuncture of diﬀerent frequencies is mediated by diﬀer-
ent types of opioid receptors: another cross-tolerance study,”
Behavioural Brain Research, vol. 47, no. 2, pp. 143–149, 1992.
[ 9 ]H .F e i ,G .X .X i e ,a n dJ . - S .H a n ,“ L o wa n dh i g hf r e q u e n c y
electroacupuncture stimulation release [Met5]enkephalin and
dynorphinAinratspinalcord,”ScienceBulletinChina,vol.32,
pp. 1496–1501, 1987.
[10] P.-L. Yi, C.-H. Tsai, J.-G. Lin, H.-J. Liu, and F.-C. Chang,
“Eﬀects of electroacupuncture at “Anmian (extra)” acupoints
onsleepactivitiesinrats:theimplicationofthecaudalnucleus
tractus solitarius,” Journal of Biomedical Science, vol. 11, no. 5,
pp. 579–590, 2004.
[11] C.-H. Cheng, P.-L. Yi, J.-G. Lin, and F.-C. Chang, “Endoge-
nous opiates in the nucleus tractus solitarius mediate
electroacupuncture-induced sleep activities in rats,” Evidence-
Based Complementary and Alternative Medicine, vol. 2011,
Article ID 159209, 11 pages, 2011.
[12] R. Norgren, “Projections from the nucleus of the solitary tract
in the rat,” Neuroscience, vol. 3, no. 2, pp. 207–218, 1978.
[13] L. J. Ryan, “Cholinergic regulation of neocortical spindling in
DBA/2 mice,” Experimental Neurology, vol. 89, no. 2, pp. 372–
381, 1985.
[14] J. Magnes, G. Moruzzi, and O. Pompeiano, “Synchronization
of the EEG produced by low-frequency electrical stimulation10 Evidence-Based Complementary and Alternative Medicine
of the region of the solitary tract,” Archives Italiennes de
Biologie, vol. 99, pp. 33–41, 1961.
[15] M. Bonvallet and M. B. Allen Jr., “Prolonged spontaneous and
evoked reticular activation following discrete bulbar lesions,”
Electroencephalography and Clinical Neurophysiology, vol. 15,
no. 6, pp. 969–988, 1963.
[16] F. Reinoso-Barbero and I. de Andres, “Eﬀects of opioid
microinjections in the nucleus of the solitary tract on the
sleep-wakefulness cycle states in cats,” Anesthesiology, vol. 82,
no. 1, pp. 144–152, 1995.
[17] R. K. Varaschin and G. S. Morato, “Selective mu- and kappa-
opioid receptor antagonists administered into the nucleus
accumbens interfere with rapid tolerance to ethanol in rats,”
Psychopharmacology, vol. 206, no. 1, pp. 85–96, 2009.
[18] R. J. Bodnar, M. J. Glass, A. Ragnauth, and M. L. Cooper,
“General,μandκopioidantagonistsinthenucleusaccumbens
alter food intake under deprivation, glucoprivic and palatable
conditions,” Brain Research, vol. 700, no. 1-2, pp. 205–212,
1995.
[19] F.-C. Chang and M. R. Opp, “Blockade of corticotropin-
releasing hormone receptors reduces spontaneous waking in
the rat,” American Journal of Physiology, vol. 275, no. 3, pp.
R793–R802, 1998.
[20] G. Paxinos and W. Watson, The Rat Brain in Stereotaxic
Coordinates, Academic Press, San Diego, Calif, USA, 4th
edition, 1998.
[21] P.-L. Yi, C.-H. Tsai, J.-G. Lin, C.-C. Lee, and F.-C. Chang,
“Kindlingstimulideliveredatdiﬀerenttimesinthesleep-wake
cycle,” Sleep, vol. 27, no. 2, pp. 203–212, 2004.
[22] J. E. Zadina, L. Hackler, L. J. Ge, and A. J. Kastin, “A potent
and selective endogenous agonist for the μ-opiate receptor,”
Nature, vol. 386, no. 6624, pp. 499–502, 1997.
[23] C. Chavkin, I. F. James, and A. Goldstein, “Dynorphin is a
speciﬁc endogenous ligand of the κ opioid receptor,” Science,
vol. 215, no. 4531, pp. 413–415, 1982.
[24] M. Waldhoer, S. Bartlett, and J. Whistler, “Opioid receptors,”
Annual Review of Biochemistry, vol. 73, pp. 953–990, 2004.
[25] D. M. Bronstein, N. C. Day, H. B. Gutstein, K. A. Trujillo, and
H.Akil,“Pre-andposttranslationalregulationofβ-endorphin
biosynthesis in the CNS: eﬀects of chronic naltrexone treat-
ment,” Journal of Neurochemistry, vol. 60, no. 1, pp. 40–49,
1993.
[26] H.S.LeeandA.I.Basbaum,“Immunoreactivepro-enkephalin
and prodynorphin products are diﬀerentially distributed
within the nucleus of the solitary tract of the rat,” Journal of
Comparative Neurology, vol. 230, no. 4, pp. 614–619, 1984.
[ 2 7 ]A .M a n s o u r ,H .K h a c h a t u r i a n ,M .E .L e w i s ,H .A k i l ,a n d
S. J. Watson, “Anatomy of CNS opioid receptors,” Trends in
Neurosciences, vol. 11, no. 7, pp. 308–314, 1988.
[ 2 8 ]N .A .A n i s ,S .C .B e r r y ,N .R .B u r t o n ,a n dD .L o d g e ,
“The dissociative anaesthetics, ketamine and phencyclidine,
selectively reduce excitation of central mammalian neurones
by N-methyl-aspartate,” British Journal of Pharmacology, vol.
79, no. 2, pp. 565–575, 1983.
[29] I. Feinberg and I. G. Campbell, “Ketamine administration
during waking increases delta EEG intensity in rat sleep,”
Neuropsychopharmacology, vol. 9, no. 1, pp. 41–48, 1993.
[30] I. Feinberg and I. G. Campell, “Stimulation of NREM delta
EEG by ketamine administration during waking: demonstra-
tion of dose dependence,” Neuropsychopharmacology, vol. 12,
no. 1, pp. 89–90, 1995.
[31] I. G. Campbell and I. Feinberg, “Comparison of MK-801 and
sleep deprivation eﬀects on NREM, REM, and waking spectra
in the rat,” Sleep, vol. 22, no. 4, pp. 423–432, 1999.